Mylotarg® (gemtuzumab ozogamicin) is an anti-CD33 mAb linked to calicheamicin, approved from 2000 to 2010 for the treatment of acute myeloid leukemia; Adcetris® (brentuximab vedotin, SGN-35) is an anti-CD30 mAb conjugated to MMAE, approved for relapsed/refractory Hodgkin lymphoma and anaplastic large-cell lymphoma; Kadcyla® (trastuzumab emtansine) is an anti-HER2 mAb conjugated to mertansine (DM1), approved for HER2 positive breast cancer; and Zevalin® and Bexxar® are two anti-CD20 mAbs conjugated with 90Yttrium and 111Indium, respectively, approved for the treatment of Non-Hodgkin lymphoma. The gene discussed is ERBB2; the disease is breast cancer.